Panel configurator
Request the FixVUE, FlexVUE and U-VUE panels you need.
Log in FlexVUE configurator U-VUE configurator FixVUE panels
Panel configurator
Request the FixVUE, FlexVUE and U-VUE panels you need.
Log in FlexVUE configurator U-VUE configurator FixVUE panels
Relevant for
Collaboration, FixVUE, InSituPlex
Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.
Presented at: ASCO 2022
Relevant for
Collaboration, FixVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry
Presented at: ASCO 2022
Relevant for
Collaboration, FixVUE, Imaging mass cytometry, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry
Senior Product Manager AI & Data Analytics
Relevant for
FlexVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Moritz will drill his way through whatever intellectual challenge you’ll put in front of him. He previously perforated biochemistry, image analysis, data science, immuno-oncology biomarkers, product management/ownership. He’ll condense the best of our ideas into a coherent roadmap. His product backlog will guide us towards our vision one step at a time.
PhD in Cellular and Genetic Medicine from the University of Copenhagen. Background in human embryonic stem cells and identification of cell of origin for various types of breast cancer. He joined Ultivue to help drive the message of just how powerful Ultivue’s mIF and same slide H&E are when combined with powerful artificial intelligence.
Associate Director, Scientific Affairs Ultivue; Chief Science Officer, OracleBio
Relevant for
FixVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
PhD in Cellular and Genetic Medicine from the University of Copenhagen. Background in human embryonic stem cells and identification of cell of origin for various types of breast cancer. He joined Ultivue to help drive the message of just how powerful Ultivue’s mIF and same slide H&E are when combined with powerful artificial intelligence.
Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.
Senior Manager, FAS, North America
Relevant for
FlexVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
PhD in Cellular and Genetic Medicine from the University of Copenhagen. Background in human embryonic stem cells and identification of cell of origin for various types of breast cancer. He joined Ultivue to help drive the message of just how powerful Ultivue’s mIF and same slide H&E are when combined with powerful artificial intelligence.
Principal Software Engineer
Relevant for
FixVUE, FlexVUE, InSituPlex, U-VUE
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
PhD in Cellular and Genetic Medicine from the University of Copenhagen. Background in human embryonic stem cells and identification of cell of origin for various types of breast cancer. He joined Ultivue to help drive the message of just how powerful Ultivue’s mIF and same slide H&E are when combined with powerful artificial intelligence.
Associate Director Scientific Affairs
Relevant for
FlexVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
PhD in Cellular and Genetic Medicine from the University of Copenhagen. Background in human embryonic stem cells and identification of cell of origin for various types of breast cancer. He joined Ultivue to help drive the message of just how powerful Ultivue’s mIF and same slide H&E are when combined with powerful artificial intelligence.
Senior Scientists, Product Development
Relevant for
FlexVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
PhD in Cellular and Genetic Medicine from the University of Copenhagen. Background in human embryonic stem cells and identification of cell of origin for various types of breast cancer. He joined Ultivue to help drive the message of just how powerful Ultivue’s mIF and same slide H&E are when combined with powerful artificial intelligence.
Relevant for
FixVUE, InSituPlex
Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.
Relevant for
FixVUE, InSituPlex, U-VUE
Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.
Senior Field Applications Scientist, Ultivue
Relevant for
FixVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
PhD in Cellular and Genetic Medicine from the University of Copenhagen. Background in human embryonic stem cells and identification of cell of origin for various types of breast cancer. He joined Ultivue to help drive the message of just how powerful Ultivue’s mIF and same slide H&E are when combined with powerful artificial intelligence.
Associate Director, Scientific Affairs; Senior Scientist, Visiopharm
Relevant for
Collaboration, FixVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
PhD in Cellular and Genetic Medicine from the University of Copenhagen. Background in human embryonic stem cells and identification of cell of origin for various types of breast cancer. He joined Ultivue to help drive the message of just how powerful Ultivue’s mIF and same slide H&E are when combined with powerful artificial intelligence.
Dr. Fabian Schneider is part of Visiopharm’s R&D and Product Management team, responsible for phenotyping products as well as service projects for custom APP development. Fabian has over 10 years of international experience in cancer biology and immuno-oncology, working in academic research labs, clinical research teams and computational pathology groups in both academia and biopharma. Fabian received his Dr phil. nat. in Cell Biology in 2011 from the Johan Wolfgang Goethe University Frankfurt, Germany.
Relevant for
Collaboration, FixVUE, InSituPlex
Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.
Catherine Benson, Keith Wharton, Gourab Chatterjee, Markus Neumann, Volker Döring and Maël Manesse
Presented at: ASCO 2022
Relevant for
Collaboration, FixVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry
